To provide services through its step-down subsidiary ‘Vayam Research Solutions Limited’
Hyderabad, April 08, 2019: Vanta Bioscience Limited (BSE: 540729) has announced that its step-down subsidiary ‘Vayam Research Solutions Limited’ has entered into a non-exclusive CRO Service Agreement with Emcure Pharmaceuticals Limited, Pune, for providing services of Bio-Analytical and Bio-Equivalence services to the Company for a period of three years from 2019 to 2022. The development was shared with BSE – the designated Stock Exchange.
The CRO Service Agreement provides for a minimum revenue assurance between Rs. 7.00 crores – Rs.9.00 crores for the financial year 2019-2020 and Rs. 20.00 crores for financial year 2020-2021.
Speaking on the development, Mr. Dopesh Raja Mulakala, Managing Director, Vanta Bioscience Limited, said, “This deal broadens our horizon. With a steady and assured revenue, we are further encouraged to shorten the timeframe for dominating the category. We now have state-of-the-art facility and world-class expertise to offer services as per global standards. We are confident that we will deliver impeccable results and add continuously value to their business. It is a matter of pride to be associated with an established company like Emcure Pharmaceuticals.”
The official spokesperson of Emcure Pharmaceuticals Ltd. added, “Service-efficiency, confidentiality and belief in team in-charge of execution are important factors for selecting the service providers for carrying out our bio-analytical and bio-equivalence studies and we believe that Vayam has the capabilities.”
Corporate Comm India(CCI Newswire)
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…